Literature DB >> 19775331

Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.

Andrea D Forman1, Michael J Hall.   

Abstract

Risk assessment coupled with genetic counseling and testing for the cancer predisposition genes BRCA1 and BRCA2 (BRCA1/2) has become an integral element of comprehensive patient evaluation and cancer risk management in the United States for individuals meeting high-risk criteria for hereditary breast and ovarian cancer (HBOC). For mutation carriers, several options for risk modification have achieved substantial reductions in future cancer risk. However, several recent studies have shown lower rates of BRCA1/2 counseling and testing among minority populations. Here, we explore the role of race/ethnicity in cancer risk assessment, genetic counseling and genetic testing for HBOC and the BRCA1/2 cancer predisposition genes. Barriers to genetic services related to race/ethnicity and underserved populations, including socioeconomic barriers (e.g., time, access, geographic, language/cultural, awareness, cost) and psychosocial barriers (e.g., medical mistrust, perceived disadvantages to genetic services), as well as additional barriers to care once mutation carriers are identified, will be reviewed.

Entities:  

Mesh:

Year:  2009        PMID: 19775331     DOI: 10.1111/j.1524-4741.2009.00798.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  50 in total

1.  Using Public-Private Partnerships to Mitigate Disparities in Access to Genetic Services: Lessons from Wisconsin.

Authors:  Laura Senier; Matthew Kearney; Jason Orne
Journal:  Adv Med Sociol       Date:  2015

2.  Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral.

Authors:  E van Riel; S van Dulmen; M G E M Ausems
Journal:  J Community Genet       Date:  2012-03-17

3.  The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation.

Authors:  Alejandra Hurtado-de-Mendoza; Monica C Jackson; Lyndsay Anderson; Vanessa B Sheppard
Journal:  J Genet Couns       Date:  2016-07-12       Impact factor: 2.537

4.  The Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality.

Authors:  Sherri L Stewart; Darryl Cooney; Shawn Hirsch; Lauren Westervelt; Thomas B Richards; Sun Hee Rim; Cheryll C Thomas
Journal:  World J Obstet Gynecol       Date:  2014-05-10

Review 5.  Disparities in gynecologic cancer genetics evaluation.

Authors:  Emily M Hinchcliff; Erica M Bednar; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2019-01-31       Impact factor: 5.482

6.  BRCA genetic counseling among at-risk Latinas in New York City: new beliefs shape new generation.

Authors:  Katarina M Sussner; Tiffany Edwards; Cristina Villagra; M Carina Rodriguez; Hayley S Thompson; Lina Jandorf; Heiddis B Valdimarsdottir
Journal:  J Genet Couns       Date:  2014-08-15       Impact factor: 2.537

7.  Attitudes of non-African American focus group participants toward return of results from exome and whole genome sequencing.

Authors:  Joon-Ho Yu; Julia Crouch; Seema M Jamal; Michael J Bamshad; Holly K Tabor
Journal:  Am J Med Genet A       Date:  2014-05-20       Impact factor: 2.802

8.  Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Authors:  Evan J Walker; Julia Carnevale; Christina Pedley; Amie Blanco; Salina Chan; Eric A Collisson; Margaret A Tempero; Andrew H Ko
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

9.  Attitudes of African Americans toward return of results from exome and whole genome sequencing.

Authors:  Joon-Ho Yu; Julia Crouch; Seema M Jamal; Holly K Tabor; Michael J Bamshad
Journal:  Am J Med Genet A       Date:  2013-05       Impact factor: 2.802

Review 10.  Understanding patient and provider perceptions and expectations of genomic medicine.

Authors:  Michael J Hall; Andrea D Forman; Susan V Montgomery; Kim L Rainey; Mary B Daly
Journal:  J Surg Oncol       Date:  2014-07-03       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.